Tingbo Liu

Prof. Tingbo Liu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
LSLiang-Wen Shi
Liang-Wen Shi
QZQuan-Quan Zhuang
Quan-Quan Zhuang
TWTai-Qin Wang
Tai-Qin Wang
XJXian-Dong Jiang
Xian-Dong Jiang
YLYue Liu
Yue Liu
JLJianzhi Liu
Jianzhi Liu
Background: Drug-resistant microbes pose a global health concern, requiring the urgent development of effective antibacterial agents and strategies in clinical practice. Therefore, there is an urgent need to explore novel antibacterial materials to effectively eliminate bacteria. The synthesis of quaternary phosphonium salt in haloargentate systems, wherein the phosphorus atom is represented in a cationic form, is a possible strategy for the development of antibacterial materials. Methods: Using (triphenyl)phosphonium-based quaternary phosphorus salts with different spacer lengths (n=2, 4, 6) as a template, we designed three kinds of quaternary phosphorus salts as effective antibacterial agents against drug-resistant bacteria. Results: The synthesized quaternary phosphorus salt of (1,4-DBTPP)Br2 effectively prevented the formation of the bacterial biofilms, and degraded bacterial membranes and cell walls by promoting the production of reactive oxygen species, which exhibited effective therapeutic effects in a rat model of a superficial wound infected with methicillin-resistant Staphylococcus aureus. Conclusion: The quaternary phosphorus salt (1,4-DBTPP)Br2 demonstrated hemocompatibility and low toxicity, revealing its potential in the treatment of clinical infections. Graphical Abstract:

2 July 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
LHLing Huang
Ling Huang
YYYong Yang
Yong Yang
ZZZhenyu Zhao
Zhenyu Zhao
SZShengsheng Zhou
Shengsheng Zhou
JWJingsong Wu
Jingsong Wu
WLWenyu Li
Wenyu Li
Section Background The data about the clinical features and outcomes of Chinese patients with peripheral T-cell lymphomas (PTCLs) are limited. AbstractSection Method This retrospective study included 1031 patients of PTCL from January 2014 to March 2022 at 21 centers in China. The clinical features, treatment patterns, and survival outcomes of the Chinese PTCL population were reported. AbstractSection Results Among the 1031 patients, 937 patients had mature T or NK cell lymphoma (91.2%). The most common subtype was extranodal NK/T-cell lymphoma, nasal type (35.5%). The median age was 52 years, most patients had stage III-IV, and fewer patients had infiltrated bone marrow. Approximately 50% of PTCL patients received anthracycline-based chemotherapies. After a median of 25.9 months of follow-up, the median overall survival (OS) and first-line progression-free survival (1 L PFS) were 83.8 and 30.5 months, respectively. Besides, the OS and 1 L PFS were significantly different among the majority of common subtypes (P < 0.05). Multivariate analysis confirmed that age, lactate dehydrogenase level, beta-2 microglobulin level, Eastern Cooperative Oncology Group Performance Status, and histologic subtypes were independent prognostic factors for survival. The CD30 was expressed across all subtypes (P < 0.05). Patients with the AITL subtype who were CD30-negative had significantly better survival outcomes than those with CD30-positive (median OS of 32.8 vs. 15.0 months, P = 0.02; median 1 L PFS of 11.0 vs. 5.2 months, P < 0.01). AbstractSection Conclusions We revealed the clinical characteristics and outcomes of PTCL patients in the real world in China, which may provide novel data on prognostic factors and primary treatment of PTCLs, applicable to routine clinical practice.

1 January 2025 in Therapeutic Advances in Hematology
Verified
Journal Article
Open access
HFHaiying Fu
Haiying Fu
TWTaiqin Wang
Taiqin Wang
YYYong Yang
Yong Yang
CQChenxi Qiu
Chenxi Qiu
HWHe Wang
He Wang
TLTingbo Liu
Tingbo Liu
Background: To evaluate the potential clinical value of cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) in the diagnosis and monitors the central nervous system (CNS) lymphomas. Methods: This was a prospective study of 17 consecutive patients with B-cell lymphoma: 10 patients with CNS lymphomas and 7 patients with B-cell lymphomas at high clinical risk of CNS relapse. Genomic profiles were performed on the CSF and plasma samples of patients by next-generation sequencing. Results: In patients with CNS lymphomas, ctDNA was detected in 70.0% of CSF and 60.0% of plasma. The detection rate and gene mutation abundance of CSF were higher than plasma ( p = 0.016). CSF had a unique genetic profile. Furthermore, we newly found that gene mutations consistent with plasma or lymphoma-related were also detected in the CSF of the high-risk group without CNS involvement. Analysis of paired plasma and CSF samples from three patients at different time points, changes of CSF ctDNA abundance occurred at the same time or earlier than clinical disease changes, which could timely monitor the therapeutic response and relapse trend. Conclusion: The detection rate of ctDNA in CSF is higher than that in plasma. The dynamic monitoring of ctDNA in CSF has hint significance for therapeutic response of CNS lymphoma patients.

5 February 2023 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
THTingxuan Huang
Tingxuan Huang
TWTaiqin Wang
Taiqin Wang
XFXuefen Fang
Xuefen Fang
PSPing Su
Ping Su
XHXiaoyun Huang
Xiaoyun Huang
TLTingbo Liu
Tingbo Liu
This study aimed to analyze the clinical characteristics and prognostic factors of patients with non-Hodgkin lymphoma (NHL) in the gastrointestinal tract.This study investigated patients (n = 456) ...

5 November 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
LPLili Pan
Lili Pan
WLWenzheng Lin
Wenzheng Lin
YQYanyan Qiu
Yanyan Qiu
JCJinhua Chen
Jinhua Chen
NLNainong Li
Nainong Li
TLTingbo Liu
Tingbo Liu
Background: Thromboembolism (TE) is a serious complication in lymphoma, driving excess morbidity and mortality. Existing prediction tools perform suboptimally in lymphoma-specific settings. Methods: We retrospectively analysed 790 newly diagnosed lymphoma patients (January 2019–December 2021). Patients were randomly split 7:3 into development and internal-validation cohorts. Forty-eight candidate predictors were screened with LASSO, followed by multivariable Cox modelling to construct a nomogram. Discrimination and calibration were assessed at 6, 12 and 24 months using time-dependent ROC analysis and bootstrap calibration. Results: TE occurred in 77/790 patients (9.8%). Independent predictors were ECOG performance status, prior venous thromboembolism (VTE), coronary artery disease, central venous catheterisation, and APTT category. The nomogram showed good discrimination: AUCs were 0.813, 0.818 and 0.733 at 0.5, 1.0 and 2.0 years in the development cohort, and 0.724, 0.731 and 0.659 in the validation cohort. Conventional scores performed poorly in this population (e.g., at 1 year ThroLy 0.587 vs. Khorana 0.527). Calibration plots indicated close agreement between predicted and observed risks. Patients who experienced TE had poorer overall survival, with the greatest divergence in survival curves occurring within the first six months after diagnosis. Conclusions: This lymphoma-specific model improves TE risk stratification and can inform individualised prophylaxis and early monitoring. External, multi-centre validation is warranted to confirm generalisability.

12 August 2026 in Hematology
Verified
Journal Article
Open access
MZMei Zhou
Mei Zhou
CLCui-Zhen Liu
Cui-Zhen Liu
ZWZhong-Qiong Wei
Zhong-Qiong Wei
SZSheng-Sheng Zhou
Sheng-Sheng Zhou
KCKai-Teng Cai
Kai-Teng Cai
JMJie Ma
Jie Ma